中国医学创新2025，Vol.22Issue(13)：70-73,4.DOI:10.3969/j.issn.1674-4985.2025.13.016
百令胶囊联合达格列净对慢性肾脏病1～2期患者临床疗效与安全性的影响
The Impact of Bailing Capsules Combined with Dapagliflozin on Clinical Efficacy and Safety of Patients with Stage 1-2 Chronic Kidney Disease
摘要
Abstract
Objective:To explore the clinical efficacy and safety of Bailing Capsules combined with Dapagliflozin in patients with stage 1-2 chronic kidney disease.Method:Eighty patients with stage 1-2 chronic kidney disease admitted to the First People's Hospital of Fuzhou from July 2022 to March 2024 were selected as the study objects,and they were divided into control group and observation group according to treatment methods,with 40 cases in each group.The control group was treated with Dapagliflozin.The observation group was treated with Bailing Capsules combined with Dapagliflozin.The clinical efficacy,TCM syndrome scores,laboratory indexes and adverse reactions were compared between the two groups.Result:The clinical effect of observation group was higher than that of control group,the difference was statistically significant(P<0.05).The TCM syndrome scores and laboratory indexes in the observation group were better than those in the control group after treatment,the differences were statistically significant(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bailing Capsules combined with Dapagliflozin has high clinical efficacy and safety in patients with stage 1-2 chronic kidney disease.It can improve immune function and renal function,and stabilize blood sugar.关键词
百令胶囊/达格列净/慢性肾脏病1～2期/安全性/中医证候积分Key words
Bailing Capsules/Dapagliflozin/Chronic kidney disease stage 1-2/Security/TCM syndrome integral引用本文复制引用
单皆,黄洁,徐健平..百令胶囊联合达格列净对慢性肾脏病1～2期患者临床疗效与安全性的影响[J].中国医学创新,2025,22(13):70-73,4.基金项目
抚州市社会发展指导性科技计划项目([2024]1号第12项) （[2024]1号第12项）
